Special Issue "Cancer Immunotherapy: Advances and Future Prospects"
Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 112028
Interests: microsatellite instability and p53 mutated colorectal cancer- tumor environment; TNBC breast cancer tumor growth and metastasis; pancreatic cancer tumor growth and metastasis; de novo purine nucleotide metabolism pathway enzymes; collagenases and cancer, tumor xenograft models; orthotropic and tail-vein experimental metastasis; patient derived xenograft models of colorectal; breast and pancreatic cancer
In this special issue, the journal will focus on Cancer Immunotherapy, its advances and future prospects. The knowledge gained in the field of cancer immunotherapy is now being applied to unleash a robust immune response against tumors after years of painstaking research. This lead to better understand the interaction between tumors and the host immune system. Cancer immunotherapy approaches including immune checkpoint inhibitor therapy, cancer vaccines, monoclonal antibodies, and adoptive cancer therapy has revolutionized traditional cancer treatment and have elicited dramatic and lasting responses in some patients. Checkpoint inhibitors like pembrolizumab and ipilimumab work by shutting down a mechanism that tumors hides from the immune system and have led to long-lasting responses occurred in patients with cancers of the skin, lung, bladder, kidney, head and neck. Cancer vaccines, consist of preventive and therapeutic vaccines, works by stimulating or restoring the ability of immune system to fight cancer. Monoclonal antibodies targets specific part of deregulated signals transduction pathways in cancer while Adoptive cancer therapy includes tumor-infiltrating lymphocytes, new strategies of CAR- and T-cell receptor -engineered T cells by genetic modifications to express specific cancer antigens and eradicate those cancer cells. Sometimes the results can be jaw-dropping when immunotherapy is complemented with existing drugs to boost their effects. However, challenges still exist in this field, includes better predicting patients response to therapy, finding targets for treatment of tumors lacking tumor-infiltrating lymphocytes also called as “immunologically cold tumors” and enhancing immunotherapy strategies by customizing immunotherapy approaches for each biological subtype. Therefore, we would like to have this special issue based on recent advances in the understanding of cancer and different immunotherapies. Adding new information on these subjects and addressing challenges and questions addressed above may lead to a better understanding of the immune response against cancer and may aid in developing cancer immunotherapies.
Dr. Sumit Agarwal
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Cancer Immunotherapy
- Immune system and response
- Tumor-host microenvironment
- Tumor-infiltrating lymphocytes
- Checkpoint inhibitors
- CAR- and T-cell receptor -engineered T cells